DOP2020000109A - Derivado de amino-flocoropiperidina como inhibidor de quinasa - Google Patents

Derivado de amino-flocoropiperidina como inhibidor de quinasa

Info

Publication number
DOP2020000109A
DOP2020000109A DO2020000109A DO2020000109A DOP2020000109A DO P2020000109 A DOP2020000109 A DO P2020000109A DO 2020000109 A DO2020000109 A DO 2020000109A DO 2020000109 A DO2020000109 A DO 2020000109A DO P2020000109 A DOP2020000109 A DO P2020000109A
Authority
DO
Dominican Republic
Prior art keywords
flocoropiperidine
derivative
amino
kinase inhibitor
present
Prior art date
Application number
DO2020000109A
Other languages
English (en)
Inventor
Youn Kim Nam
Hee Lee Jun
Woo Kim In
Hwarn Jeong Seung
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Publication of DOP2020000109A publication Critical patent/DOP2020000109A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a un compuesto representado por la siguiente Fórmula Química 1, o a una sal farmacéuticamente aceptable del mismo, y el compuesto según la presente invención puede usarse de manera útil para la prevención o el tratamiento de enfermedades que están asociadas con acciones inhibidoras de quinasas.
DO2020000109A 2017-12-28 2020-06-10 Derivado de amino-flocoropiperidina como inhibidor de quinasa DOP2020000109A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170183060A KR102577241B1 (ko) 2017-12-28 2017-12-28 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
PCT/KR2018/016812 WO2019132560A1 (ko) 2017-12-28 2018-12-28 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체

Publications (1)

Publication Number Publication Date
DOP2020000109A true DOP2020000109A (es) 2020-09-30

Family

ID=67063980

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2020000109A DOP2020000109A (es) 2017-12-28 2020-06-10 Derivado de amino-flocoropiperidina como inhibidor de quinasa

Country Status (22)

Country Link
US (1) US11078206B2 (es)
EP (1) EP3733671B1 (es)
JP (1) JP7032535B2 (es)
KR (1) KR102577241B1 (es)
CN (1) CN111491934B (es)
AU (1) AU2018394995B2 (es)
BR (1) BR112020013164A2 (es)
CA (1) CA3084777C (es)
CL (1) CL2020001754A1 (es)
DO (1) DOP2020000109A (es)
EC (1) ECSP20035222A (es)
ES (1) ES2923682T3 (es)
MA (1) MA51429A (es)
MX (1) MX2020006708A (es)
MY (1) MY196186A (es)
PE (1) PE20210548A1 (es)
PH (1) PH12020551014A1 (es)
RU (1) RU2762637C1 (es)
SA (1) SA520412333B1 (es)
SG (1) SG11202004918XA (es)
TN (1) TN2020000125A1 (es)
WO (1) WO2019132560A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102119223A (zh) 2008-05-16 2011-07-06 生命技术公司 用于测量细胞增殖的双标记法
KR20200036004A (ko) 2017-08-01 2020-04-06 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 키나아제 억제제로서 피라졸로 및 트리아졸로 비시클릭 화합물
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
KR102318929B1 (ko) 2017-12-28 2021-10-28 주식회사 대웅제약 카이네이즈 저해제로서의 옥시-플루오로피페리딘 유도체
CN113498352A (zh) 2019-01-23 2021-10-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-三唑并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪
JP7374309B2 (ja) 2019-09-23 2023-11-06 ピーエムブイ ファーマシューティカルズ， インコーポレイテッド 変異体ｐ５３機能を復元させるための方法および化合物
WO2021108803A1 (en) 2019-11-26 2021-06-03 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as jak inhibitors
WO2021147952A1 (zh) * 2020-01-21 2021-07-29 江苏先声药业有限公司 嘧啶并吡咯类化合物
WO2021147953A1 (zh) * 2020-01-21 2021-07-29 江苏先声药业有限公司 嘧啶并五元环类衍生物及其应用
JP2023533447A (ja) 2020-06-24 2023-08-03 ピーエムブイ ファーマシューティカルズ， インコーポレイテッド がんを処置する併用療法
WO2022062601A1 (zh) * 2020-09-22 2022-03-31 江苏先声药业有限公司 嘧啶并吡咯类化合物
CN114315838A (zh) * 2020-09-30 2022-04-12 江苏先声药业有限公司 嘧啶并吡咯类化合物
WO2023147419A2 (en) 2022-01-27 2023-08-03 Pmv Pharmaceuticals, Inc. Deuterated compounds for restoring mutant p53 function

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
JP5369183B2 (ja) 2008-07-16 2013-12-18 ファーマサイクリックス，インク． 固形腫瘍の治療用のブルートンのチロシンキナーゼの阻害剤
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
DK2975042T3 (en) * 2010-06-23 2019-01-21 Hanmi Science Co Ltd Novel fused pyrimidine derivatives to inhibit tyrosine kinase activity
MD20140023A2 (ro) 2011-09-22 2014-06-30 Pfizer Inc. Derivaţi de pirolpirimidină şi purină
RU2018104702A (ru) * 2012-08-06 2019-02-22 Ацея Байосайенсиз Инк. Новые соединения пирролопиримидина в качестве ингибиторов протеинкиназ
US9840517B2 (en) * 2013-09-18 2017-12-12 Beijing Hanmi Pharmaceutical Co., Ltd. Compound inhibiting activities of BTK and/or JAK3 kinases
MD4649C1 (ro) 2013-12-05 2020-04-30 Pfizer Inc. Pirol[2,3-d]pirimidinil, pirol[2,3-b]pirazinil şi pirol[2,3-d]piridinil acrilamide
CN105732637B (zh) * 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
JP2018537502A (ja) * 2015-12-16 2018-12-20 サウザーン リサーチ インスチチュート ピロロピリミジン化合物、キナーゼｌｒｒｋ２阻害剤としての使用、及びその調製方法
EP3950691A1 (en) 2016-06-30 2022-02-09 Daewoong Pharmaceutical Co., Ltd. Pyrazolopyrimidine derivatives as kinase inhibitor
KR102032418B1 (ko) 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
CN111491934B (zh) 2022-08-30
PE20210548A1 (es) 2021-03-17
US20200299298A1 (en) 2020-09-24
JP7032535B2 (ja) 2022-03-08
MA51429A (fr) 2021-04-07
MY196186A (en) 2023-03-21
WO2019132560A1 (ko) 2019-07-04
SG11202004918XA (en) 2020-06-29
AU2018394995A1 (en) 2020-06-25
AU2018394995B2 (en) 2021-05-13
EP3733671A4 (en) 2021-06-09
RU2762637C1 (ru) 2021-12-21
ES2923682T3 (es) 2022-09-29
KR20190080540A (ko) 2019-07-08
TN2020000125A1 (en) 2022-01-06
JP2021505644A (ja) 2021-02-18
CA3084777C (en) 2022-08-30
CN111491934A (zh) 2020-08-04
CL2020001754A1 (es) 2020-11-27
BR112020013164A2 (pt) 2020-12-01
MX2020006708A (es) 2020-08-20
SA520412333B1 (ar) 2022-12-08
EP3733671A1 (en) 2020-11-04
ECSP20035222A (es) 2020-07-31
US11078206B2 (en) 2021-08-03
KR102577241B1 (ko) 2023-09-11
CA3084777A1 (en) 2019-07-04
NZ765159A (en) 2023-09-29
PH12020551014A1 (en) 2021-08-16
EP3733671B1 (en) 2022-06-29

Similar Documents

Publication Publication Date Title
CL2020001754A1 (es) Derivado de amino-fluoropiperidina como inhibidor de quinasa.
ECSP20035588A (es) Derivado de amino-metil piperidina como inhibidor de quinasa
ECSP18093777A (es) Derivados de pirazolopirimidina como inhibidor de quinasa
DOP2020000112A (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
CO2019004034A2 (es) Compuesto de piridina
CU20160111A7 (es) Compuestos de heterociclilo bicíclico como inhibidores de irak4
CO2017012067A2 (es) Derivado de pirido[3,4–d]pirimidina y sal farmacéuticamente aceptable de éste
ECSP17029203A (es) Inhibidor de cinasa aurora a
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
DOP2019000194A (es) Derivados de pirrolotriazina como inhibidor de cinasas